8th October 2021

“In this first episode, Prof Oliver FitzGerald and Atturos CSO Prof Stephen Pennington talk to Gráinne O’Leary about psoriatic arthritis, how it’s diagnosed, its symptoms and impact, and patients’ unmet needs. They also discuss HIPPOCRATES the recently funded IMI (Innovative Medicines Initiative) public private research consortium which aims to address unmet needs in psoriatic disease and develop personalised treatment options for those affected.”

8th July 2021

Steve Pennington (Atturos CSO) and Oliver FitzGerald (Atturos Clinical Leadership Team and GRAPPA Co-President) were joined by senior scientists James Waddington and Orla Coleman to present project updates at the international GRAPPA 2021 meeting. The presentation provided GRAPPA network with an update of progress on two important strategic research projects with Lilly and Pfizer.

30th June 2021

Steve was the invited Opening Keynote speaker at TECHNOLOGY NETWORKS, Advances in Proteomics & Metabolomics 2021 – from research to the clinic. The event, attracting over 1,100 registrants, brought together world leading experts to discuss the role of proteomics approaches in understanding disease and the development of novel clinical biomarkers. 

11th June 2021

Read our latest publication “Identification and Evaluation of Serum Protein Biomarkers Which Differentiate Psoriatic from Rheumatoid Arthritis”.

11th January 2021

Atturos are pleased to announce that following the completion of a business case analysis, it has negotiated a worldwide exclusive license agreement for patent WO 2020/025721 “A method of diagnosing or prognosing psoriatic arthritis” from University College Dublin. The patent underpins the serum protein ‘PsARADx’ assay which can discriminate patients with psoriatic arthritis from those with rheumatoid arthritis. Atturos is looking forward to beginning the next steps in developing the assay which has the potential to improve psoriatic arthritis patient outcomes.

20th November 2020

Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management

30th October 2020

Read our latest application note "From Nanoflow to Standard Flow LC/MS for Routine Quantitative Plasma Proteomics in Diabetic Kidney Disease Research".

6th October 2020

Applying precision medicine to unmet clinical needs in psoriatic disease.

21st May 2020

SCREENED: A Multistage Model of Thyroid Gland Function for Screening Endocrine-Disrupting Chemicals in a Biologically Sex-Specific Manner 

7th November 2019

Founder and Chief Scientific Officer Prof. Stephen Pennington presents Atturos work at the Clinical and Pharmaceutical Solutions through Analysis Symposium in Philadelphia, Pennsylvania, U.S.A on the 28th of October 2019.

16th September 2019

Diagnostic Blood Test to Predict Onset of Diabetic Kidney Disease One Step Closer to Launch Across Europe.

1st March 2019

Orla Coleman (BSc, PhD) joins the Atturos Scientific Team as a Senior Scientist!

7th December 2018

Prof. Stephen Pennington was presented with the NovaUCD 2018 innovation award...

23rd April 2018

Atturos is pleased to announce it has begun a significant collaboration with Merck KGaA. “The projects sees Atturos developing important LC-MS workflows for Merck KGaA and marks what both companies hope will be a series of ongoing collaborative projects” notes Dave Corr, CEO Atturos Ltd.

11th April 2018

Steve presents Atturos’ MRM workflows at the Analytica Conference, Munich, Germany.

17th September 2017

Atturos Founder and CSO Stephen Pennington hosts the 16th Human Proteome Organisation World Congress in Dublin. 

31st March 2017

Atturos Stephen Pennington features in The Irish Times announcing the finalists of the AIBstart-up Academy

28th May 2016

The third and final Atturos brainstorming session was focussed on Business Development and was held today in NovaUCD...

16th March 2016

As part of our continuous clinical and market research efforts Atturos CEO Stephen Pennington attended the European Association of Urology Annual Meeting this past weekend.

2nd September 2021

Oliver FitzGerald (Atturos Clinical Leadership Team and GRAPPA Co-President) has been recognised as a Master of the American College of Rheumatology. This is one of the highest honours the College bestows to members who have made outstanding contributions to the field of rheumatology through scholarly achievement and/or service to their patients, students, and profession. Congratulations Oliver!

2nd July 2021

HIPPOCRATES combines 26 different research partners, SMEs, pharmaceutical companies, and patient organisations in promoting early identification and improving outcomes for patients with psoriatic arthritis. The consortium is co-led by Stephen Pennington, Atturos CSO, and Oliver FitzGerald, Atturos Head of Clinical Affairs Rheumatology. Download a copy of the full press release here, and visit the website for more information

24th June 2021

Atturos recent funding successes and the future directions of our product development have appeared in a Sunday Business Post article ‘Making it Work: Medical start-up Atturos gets €700k for arthritic research’. In the article Steve, Atturos founder and CSO, discusses the next stages in Atturos business development including the recruitment of a CEO. To read the article click below.

22nd April 2021

Atturos is delighted to announce it has secured €1.57m funding from the third round of the Disruptive Technologies Innovation Fund. In collaboration with Agilent Technologies Ireland, Neoteryx and UCD, the consortium will develop the first innovative plasma sampling device for inflammatory diseases. We are excited to move PERSONA (Patient Centric Sampling for a New Diagnostic Pathway) forward, and look forward to updating you all soon with further information!

1st December 2020

We all know it's been a challenging year, so we used the 1st of December as an excuse to decorate the office, put on our festive jumpers and switch on the Atturos office Christmas tree lights! Thanks to our fantastic research assistant Joy for doing the honours.

17th November 2020

Following the grant of the “Prostate Cancer Biomarkers” patent in Europe, Atturos have now been granted a US wide patent (US 15/106,582) derived from International patent application (PCT/EP2014/078914).

21st October 2020

Read our latest publication "A robust multiplex immunoaffinity mass spectrometry assay (PromarkerD) for clinical prediction of diabetic kidney disease". This work represents a collaborative effort between the Atturos Team, Proteomics International (Perth) and Sydney Mass Spectrometry.

25th September 2020

As our team and portfolio are quickly expanding, our website needed to grow with us... welcome to the new look website! If you have any feedback, please let us know!

30th January 2020

"20 health and medtech start-ups with their finger on the pulse"

30th September 2019

100 Hot Start Ups – The Sunday Business Post . The companies driving Irelands entrepreneurial edge.

​

Atturos Ltd is delighted to be recognised amongst The Sunday Business Post’s latest list of Irish entrepreneurial companies.

1st September 2019

Joy Zhou (BSc, MSc) joins the Atturos Scientific Team as a Research Assistant!

19th February 2019

​In February 2019 the SCREENED project was kicked off following the launch of the EURION cluster in Brussels, Belgium

19th September 2018

Proteomics International and Irish clinical diagnostics company Atturos have signed a Memorandum of Understanding that will see the companies join forces to develop novel diagnostic tests for the European region.

16th April 2018

Atturos Founder and Chief Scientific Officer Steve Pennington presents at an Agilent hosted press briefing during the American Association for Cancer Research Annual Meeting 2018.

16th March 2018

Identification and evaluation of serum protein biomarkers for organ confined prostate cancer.

15th June 2017

The Atturos lab opens in the Conway Institute, UCD, Dublin. See what we are focussing on!

10th February 2017

CSO, Stephen Pennington was in Rome for the signing of the agreement.

16th May 2016

Last Friday May 13th Atturos hosted a Clinical and Technical Brainstorming session in NovaUCD as part of our market analysis to obtain and evaluate customer and end user attitudes towards the OCProDx test...

25th August 2021

“In this expert webinar, Prof. Stephen Pennington, Dr. Orla Coleman, and Dr. James Waddington outline the importance of better diagnostic tests and data to address unmet clinical needs in chronic diseases. They explain how this diagnostic data can be obtained through an integrated workflow that enables simplified, robust, reproducible, and cost-effective analysis of readily collected human samples. Using supporting illustrative data, the Atturos team demonstrate how it will be possible to use clinical research measurements for precision medicine”

2nd July 2021

Orla Coleman, Atturos Senior Scientist, presented results from the recently completed Atturos GRAPPA- Lilly project “Identification of serum protein biomarkers at baseline to distinguish radiographic progressors from non-progressors in patients with active Psoriatic Arthritis” at the IFPA 6th WPPAC. Orla’s presentation introduced the unmet clinical need to identify Psoriatic arthritis patients who are risk of progression to radiographic damage. The presentation outlines the work Atturos has undertaken to use targeted proteomics and data analysis by machine learning methods to identify a biomarker signature and algorithm that may predict disease progression.

21st June 2021

Led by Atturos CSO Steve Pennington, with contributions from Senior Scientist James Waddington, ‘Biomarkers for improved management of prostate cancer’ has been selected as a feature article in Clinical Laboratory International (CLI). The article describes challenges in the clinical management of prostate cancer, limitations to current screening and diagnostic strategies and the future of biomarker tests for personalized prostate cancer patient care. To read the full article download a copy here, or click on the link below to visit CLI

18th January 2021

BMC Clinical Proteomics, part of Springer Nature, selected "Clinical proteomics for prostate cancer" as the feature article for January and February 2021. The review, led by Atturos CSO Steve Pennington, discusses high throughput proteomic technologies as a potential solution for the current challenges faced in diagnosing and treating prostate cancer.

22nd November 2020

Steve presented on the "Development and Delivery of Advanced Protein Tests for an Era of Precision Medicine". For further information on PSI 2020 visit their website!

16th November 2020

The Atturos management team have undertaken and completed a business case analysis for the commercial feasibility of a serum protein assay – PsARADx. The assay is protected under UCD patent application WO 2020/025721and provides “A method of diagnosing or prognosing psoriatic arthritis”.  The analysis undertaken included engagement with key stakeholders. Atturos is now in negotiations with UCD to acquire a license to the patent.

16th October 2020

Atturos founder, Steve Pennington, and Senior Scientist, James Waddington, played a key role in publication of the Human Proteome Project’s blueprint of the Human Proteome 'A high-stringency blueprint of the human proteome'. 

2nd June 2020

New €16 million EU and industry-supported international research consortium aims to improve obesity treatment and change the narrative around obesity

Twenty-nine leading partners from civil society, academia and industry in 12 countries have joined forces to better understand obesity and optimise future treatment

6th January 2020

James Waddington (MBiolSci, PhD) joins the Atturos Scientific Team as a Senior Scientist!

18th September 2019

Orla Coleman (Atturos) and Scott Bringans (PILL) present the poster "PromarkerD as an immunoaffinity mass spectrometry assay for diabetic kidney disease"

17th July 2019

Atturos are pleased to announce that the European patent filing (EP3084444) derived from International patent application (PCT/EP2014/078914) for “Prostate Cancer Biomarkers” has been granted. The patent supports the on-going protection of OCProDx. 

16th January 2019

The new European collaborative project SCREENED aims to develop three-dimensional (3D)
cellbased in vitro tests to better characterize the effects of endocrine disruptors on thyroid gland function.

5th September 2018

Twelve start-ups pitched their new technology solutions to investors at the 10th annual innovation showcase event BIG IDEAS. Atturos were shortlisted and presented OCProDx to an invited audience of Irish research and business communities 

16th February 2018

Steve Pennington invited to join Oxford Global Biomarkers Directors Club and presents at 13th Annual Congress, Manchester, U.K.

24th January 2018

Atturos development and delivery of MassSpec based multiplexed biomarker assays was presented by Steve Pennington at a lunchtime workshop hosted by Agilent at the Mass Spectrometry Applications to the Clinical Lab 10th Annual Conference Palm Springs, California, U.S.A.

30th April 2017

Listen to Stephen Pennington telling the story of Atturos...

21st December 2016

We are delighted to announce that Professor Jennifer Van Eyk has today joined the Atturos Advisory Board. 

25th April 2016

Members of the Atturos team attended the 2nd Annual John Fitzpatrick Prostate Cancer Conference last week in the Aviva Stadium in Dublin.